Research Topics
Species | Andrew B LassmanSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Molecular biology of gliomasAndrew B Lassman
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Neurol Neurosci Rep 4:228-33. 2004..Each of these abnormalities is described in detail. Efforts to inhibit abnormally activated pathways are underway through multi-institutional clinical trials...- Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Andrew B Lassman
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 11:7841-50. 2005.... - Systemic high-dose intravenous methotrexate for central nervous system metastasesAndrew B Lassman
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Neurooncol 78:255-60. 2006..Rapid infusion of high-dose intravenous methotrexate (HD IV MTX) penetrates the blood-brain barrier (BBB) and has reported activity in leptomeningeal metastases... - Incorporating molecular tools into clinical trials and treatment for gliomas?Andrew B Lassman
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Curr Opin Neurol 20:708-11. 2007..Knowledge of the molecular biology of gliomas may improve therapy. This review highlights several recent studies on this topic... - Metastases to the pineal glandAndrew B Lassman
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Neurology 67:1303-4. 2006..Hence, metastatic disease, albeit uncommon, should be considered in the differential diagnosis of pineal tumors... 
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman
Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Neuro Oncol 13:649-59. 2011..Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1p19q deletion. Ongoing trials will address these issues prospectively...- Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
Neuro Oncol 14:761-7. 2012..01), and frontal lobe predominance (P < .05). Limited level 1 evidence is currently available to guide treatment decisions, and ongoing phase III trials will be critical to understanding the optimal therapy... - A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyJeffrey J Raizer
Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Neuro Oncol 12:95-103. 2010..001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT... - Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto
The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Neuro Oncol 13:1244-51. 2011..4, P< .0001). Longitudinal increases in serum YKL-40 are associated with increased risk of death in patients with glioblastomas and anaplastic gliomas. YKL-40 is also a putative indicator of disease status in these patients... 
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto
The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Neurooncol 105:607-12. 2011..Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival...- Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade gliomaLauren Q Shapiro
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Int J Radiat Oncol Biol Phys 85:636-42. 2013..The objective of this study was to characterize the patterns of failure after this treatment regimen... - "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Neuro Oncol 13:1364-9. 2011..Pulsatile erlotinib can control CNS metastases from EGFR mutant lung cancer after failure of standard daily dosing. CNS disease may not harbor acquired resistance mutations that develop systemically. A prospective trial is planned... - Survey of treatment recommendations for anaplastic oligodendrogliomaLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Neuro Oncol 9:314-8. 2007.... - A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer
Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Neuro Oncol 12:87-94. 2010..This has important implications for further development of this drug in the treatment of MG as well as the optimal management of patients with other malignancies such as NSCLC who are on enzyme-inducing drugs... - A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastasesFabio M Iwamoto
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
J Neurooncol 87:85-90. 2008..To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors... - High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancerJennifer L Clarke
Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
J Neurooncol 99:283-6. 2010..However, intermittent (pulsatile) high dose administration (1000-1500 mg/week) achieves a higher CSF concentration than standard dosing, and successfully controlled LM in this patient... - Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastomaJennifer L Clarke
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
J Clin Oncol 27:3861-7. 2009..The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM... - Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant gliomaAntonio Omuro
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Neuro Oncol 15:242-50. 2013..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)... - Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco
Human Oncology and Pathogenesis Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Discov 2:458-71. 2012..Here, we demonstrate selective sensitivity of glioma-specific EGFR mutants to ATP-site competitive EGFR kinase inhibitors that target the inactive conformation of the catalytic domain... - Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional statusMarsha Reyngold
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
J Neurooncol 110:369-74. 2012..Grade 3-4 hematologic toxicity occurred in 11 patients. Abbreviated RT with concurrent TMZ provides a clinical benefit, is safe and tolerable in patients of advanced age or poor functional status... - Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitorsSamuel A Goldlust
Department of Neurology and the Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Neurooncol 107:407-11. 2012..Prior exposure to VEGFR-TKIs may not preclude response to BEV, but sensitivity to BEV may be lower following more robust VEGFR inhibition... - YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger
Brain Tumor Center, New York, NY, USA
Ann Neurol 70:163-9. 2011..To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL)... - Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomasGaurav D Shah
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Neurooncol 85:217-22. 2007..Disease control may also correlate with hematologic toxicity (p = 0.08), suggesting that glioma and marrow stem cells may share a common sensitivity to this chemotherapy regimen... - Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancerKevin C De Braganca
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Neurooncol 100:443-7. 2010..This series suggests bevacizumab may be safe and effective for progressive brain metastases from NSCLC and deserves further study... - Signal transduction inhibitors and antiangiogenic therapies for malignant gliomaIngo K Mellinghoff
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
Glia 59:1205-12. 2011..2011 Wiley-Liss, Inc... - Advances in the treatment of malignant gliomasMustafa Khasraw
Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Curr Oncol Rep 12:26-33. 2010..This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy... - Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directionsDouglas E Ney
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Curr Oncol Rep 11:62-7. 2009..Other molecular alterations found in oligodendrogliomas include hypermethylation of the promoter for the MGMT gene, TP53 mutations, EGFR and platelet-derived growth factor/PDGFR alterations, and 9p and 10q loss... - Steroid management in newly diagnosed glioblastomaMariel B Deutsch
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
J Neurooncol 113:111-6. 2013..Steroids are often tapered during RT, but there is frequent taper failure with this approach. A prospective trial with standardized steroid dosing regimens would be needed to verify these findings... - Glioma oncogenesis and animal models of glioma formationYelena Lyustikman
Department of Cancer Biology, Memorial Sloan-Kettering Cancer Center, 408 East 69th Street, Z1319, New York, NY 10021, USA
Hematol Oncol Clin North Am 20:1193-214. 2006..Animal models are important not only for the testing of novel therapeutics but also as a means to understand the molecular explanations for treatment success and failure in humans... - Brain metastasesAndrew B Lassman
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Neurol Clin 21:1-23, vii. 2003..This article reviews the epidemiology, clinical features, treatment, and prognosis of brain metastases from system malignancies... - Response of glioblastomas to EGFR kinase inhibitorsAndrew B Lassman
N Engl J Med 354:525-6; author reply 525-6. 2006 - Salvage temozolomide for prior temozolomide respondersEnrico Franceschi
Department of Medical Oncology, Bellaria Hospital, Bologna, Italy
Cancer 104:2473-6. 2005..CONCLUSIONS: TMZ was found to be well tolerated and effective in this setting, suggesting that repeat use of TMZ in previous responders warrants further investigation...